Glaucoma Research Foundation receives $1.6 million gift

Article

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma.

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma. “The Barrs have been very generous in their support of glaucoma research and their gift will have a major impact on the effort to find new treatments and eventually a cure for glaucoma,” said Thomas Brunner, president and CEO of Glaucoma Research Foundation.

The Catalyst For a Cure research consortium is in its ninth year and takes a unique approach to glaucoma research. Unlike conventional research, which often operates in isolation until results can be published, the Catalyst For a Cure was formed with the goal of real time collaboration to speed the process of discovery. Four principal scientists at four universities brought their experience in neuroscience, genetics, molecular biology and vision to curing glaucoma, the second leading cause of blindness worldwide. Together the team has accelerated the pace of discovery and brought new understanding to vision loss from glaucoma. The principal scientists include Monica Vetter, PhD, University of Utah, Nick Marsh-Armstrong, PhD, Johns Hopkins University, Phil Horner, PhD, University of Washington, and David Calkins, PhD, Vanderbilt University.

Read more about the work of CFC.

www.glaucoma.org

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.